BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford WJ, Serhan CN, Parkinson JF. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J 2007;21:3877-84. [PMID: 17625069 DOI: 10.1096/fj.07-8653com] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Boudreau LH, Picot N, Doiron J, Villebonnet B, Surette ME, Robichaud GA, Touaibia M. Caffeoyl and cinnamoyl clusters with anti-inflammatory and anti-cancer effects. Synthesis and structure–activity relationship. New J Chem 2009;33:1932. [DOI: 10.1039/b907878a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
2 Shimizu S, Ogawa T, Seno S, Kouzaki H, Shimizu T. Pro-Resolution Mediator Lipoxin A4 and its Receptor in Upper Airway Inflammation. Ann Otol Rhinol Laryngol 2013;122:683-9. [DOI: 10.1177/000348941312201104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
3 Mishra A, Yao X, Levine SJ. From bedside to bench to clinic trials: identifying new treatments for severe asthma. Dis Model Mech 2013;6:877-88. [PMID: 23828644 DOI: 10.1242/dmm.012070] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
4 Carlo T, Levy BD. Chemical mediators and the resolution of airway inflammation. Allergol Int 2008;57:299-305. [PMID: 18946231 DOI: 10.2332/allergolint.08-RAI-0018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
5 Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol 2016;16:51-67. [PMID: 26688348 DOI: 10.1038/nri.2015.4] [Cited by in Crossref: 250] [Cited by in F6Publishing: 239] [Article Influence: 35.7] [Reference Citation Analysis]
6 Abma W, Noreby M, Wheelock CE, Dahlén SE, Adner M, Säfholm J. Lipoxin A4 reduces house dust mite and TNFα-induced hyperreactivity in the mouse trachea. Prostaglandins Other Lipid Mediat 2020;149:106428. [PMID: 32070748 DOI: 10.1016/j.prostaglandins.2020.106428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhu M, Wang X, Sun L, Schultzberg M, Hjorth E. Can inflammation be resolved in Alzheimer's disease? Ther Adv Neurol Disord 2018;11:1756286418791107. [PMID: 30116300 DOI: 10.1177/1756286418791107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
8 Miyata J, Fukunaga K, Kawashima Y, Ohara O, Kawana A, Asano K, Arita M. Dysregulated metabolism of polyunsaturated fatty acids in eosinophilic allergic diseases. Prostaglandins Other Lipid Mediat 2020;150:106477. [PMID: 32711128 DOI: 10.1016/j.prostaglandins.2020.106477] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hisada T, Ishizuka T, Aoki H, Mori M. Resolvin E1 as a novel agent for the treatment of asthma. Expert Opin Ther Targets 2009;13:513-22. [PMID: 19368495 DOI: 10.1517/14728220902865622] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
10 Carlo T, Levy BD. Molecular circuits of resolution in airway inflammation. ScientificWorldJournal 2010;10:1386-99. [PMID: 20623098 DOI: 10.1100/tsw.2010.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Barnig C, Levy BD. Innate immunity is a key factor for the resolution of inflammation in asthma. Eur Respir Rev 2015;24:141-53. [PMID: 25726564 DOI: 10.1183/09059180.00012514] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
12 Ni CM, Yang W, Wan KS. Serum levels of lipoxin A(4) do not predict the development of subsequent asthma among young children with acute bronchiolitis. J Asthma 2011;48:576-80. [PMID: 21671842 DOI: 10.3109/02770903.2011.587582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Liu J, Peng L, Li J. The Lipoxin A4 Receptor Agonist BML-111 Alleviates Inflammatory Injury and Oxidative Stress in Spinal Cord Injury. Med Sci Monit 2020;26:e919883. [PMID: 31971927 DOI: 10.12659/MSM.919883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Navarro-Xavier RA, de Barros KV, de Andrade IS, Palomino Z, Casarini DE, Flor Silveira VL. Protective effect of soybean oil- or fish oil-rich diets on allergic airway inflammation. J Inflamm Res 2016;9:79-89. [PMID: 27274303 DOI: 10.2147/JIR.S102221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
15 Wu J, Ding DH, Li QQ, Wang XY, Sun YY, Li LJ. Lipoxin A4 Regulates Lipopolysaccharide-Induced BV2 Microglial Activation and Differentiation via the Notch Signaling Pathway. Front Cell Neurosci 2019;13:19. [PMID: 30778288 DOI: 10.3389/fncel.2019.00019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
16 Kure I, Nishiumi S, Nishitani Y, Tanoue T, Ishida T, Mizuno M, Fujita T, Kutsumi H, Arita M, Azuma T. Lipoxin A(4) reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation. J Pharmacol Exp Ther. 2010;332:541-548. [PMID: 19846590 DOI: 10.1124/jpet.109.159046] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
17 Hilberath JN, Carlo T, Pfeffer MA, Croze RH, Hastrup F, Levy BD. Resolution of Toll-like receptor 4-mediated acute lung injury is linked to eicosanoids and suppressor of cytokine signaling 3. FASEB J 2011;25:1827-35. [PMID: 21321188 DOI: 10.1096/fj.10-169896] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
18 Haworth O, Levy BD. Lipoxins, resolvins and protectins: new leads for the treatment of asthma. Expert Opin Drug Discov 2008;3:1209-22. [PMID: 23489078 DOI: 10.1517/17460441.3.10.1209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
19 Levy BD, Serhan CN. Resolution of acute inflammation in the lung. Annu Rev Physiol 2014;76:467-92. [PMID: 24313723 DOI: 10.1146/annurev-physiol-021113-170408] [Cited by in Crossref: 168] [Cited by in F6Publishing: 151] [Article Influence: 18.7] [Reference Citation Analysis]
20 Papanicolaou A, Wang H, Satzke C, Vlahos R, Wilson N, Bozinovski S. Novel Therapies for Pneumonia-Associated Severe Asthma Phenotypes. Trends Mol Med 2020;26:1047-58. [PMID: 32828703 DOI: 10.1016/j.molmed.2020.07.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Serhan CN. Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukot Essent Fatty Acids. 2008;79:157-163. [PMID: 19008087 DOI: 10.1016/j.plefa.2008.09.012] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
22 Jaén RI, Sánchez-García S, Fernández-Velasco M, Boscá L, Prieto P. Resolution-Based Therapies: The Potential of Lipoxins to Treat Human Diseases. Front Immunol 2021;12:658840. [PMID: 33968061 DOI: 10.3389/fimmu.2021.658840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
23 Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol. 2008;153 Suppl 1:S200-S215. [PMID: 17965751 DOI: 10.1038/sj.bjp.0707489] [Cited by in Crossref: 217] [Cited by in F6Publishing: 235] [Article Influence: 14.5] [Reference Citation Analysis]
24 Simões R, Niconi-de-almeida Y, da-Fé A, Barja-fidalgo C, Fierro I. A synthetic analog of 15-epi-lipoxin A4 inhibits human monocyte apoptosis: Involvement of ERK-2 and PI3-kinase. Prostaglandins & Other Lipid Mediators 2010;91:10-7. [DOI: 10.1016/j.prostaglandins.2009.12.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
25 Planaguma A, Levy BD. Uncontrolled airway inflammation in lung disease represents a defect in counter-regulatory signaling. Future Lipidol 2008;3:697-704. [PMID: 19293940 DOI: 10.2217/17460875.3.6.697] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
26 Knolle MD, Owen CA. ADAM8: a new therapeutic target for asthma. Expert Opin Ther Targets 2009;13:523-40. [PMID: 19397475 DOI: 10.1517/14728220902889788] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
27 Fu T, Mohan M, Brennan EP, Woodman OL, Godson C, Kantharidis P, Ritchie RH, Qin CX. Therapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease. ACS Pharmacol Transl Sci 2020;3:43-55. [PMID: 32259087 DOI: 10.1021/acsptsci.9b00097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
28 Wang Y, He G, Wang F, Zhang C, Ge Z, Zheng X, Deng H, Yuan C, Zhou B, Tao X, Zhang J, Tang K. Aspirin inhibits adipogenesis of tendon stem cells and lipids accumulation in rat injury tendon through regulating PTEN/PI3K/AKT signalling. J Cell Mol Med 2019;23:7535-44. [PMID: 31557405 DOI: 10.1111/jcmm.14622] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
29 Montero-Melendez T, Patel HB, Seed M, Nielsen S, Jonassen TE, Perretti M. The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. Am J Pathol 2011;179:259-69. [PMID: 21703408 DOI: 10.1016/j.ajpath.2011.03.042] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
30 Stopka-farooqui U, Haworth O. Proresolving mediators: new therapies to treat inflammatory diseases. Clinical Lipidology 2015;10:343-50. [DOI: 10.2217/clp.15.19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Kong X, Wu SH, Zhang L, Chen XQ. Pilot application of lipoxin A4 analog and lipoxin A4 receptor agonist in asthmatic children with acute episodes. Exp Ther Med 2017;14:2284-90. [PMID: 28962156 DOI: 10.3892/etm.2017.4787] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
32 Hasturk H, Kantarci A, Van Dyke TE. Paradigm shift in the pharmacological management of periodontal diseases. Front Oral Biol 2012;15:160-76. [PMID: 22142963 DOI: 10.1159/000329678] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
33 Wu B, Walker JA, Temmermand D, Mian K, Spur B, Rodriguez A, Stein TP, Banerjee P, Yin K. Lipoxin A(4) promotes more complete inflammation resolution in sepsis compared to stable lipoxin A(4) analog. Prostaglandins Leukot Essent Fatty Acids 2013;89:47-53. [PMID: 23688707 DOI: 10.1016/j.plefa.2013.04.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
34 Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt AS, Wark PA, Hutchinson A, Irving LB, Levy BD, Anderson GP. Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A 2012;109:935-40. [PMID: 22215599 DOI: 10.1073/pnas.1109382109] [Cited by in Crossref: 107] [Cited by in F6Publishing: 110] [Article Influence: 10.7] [Reference Citation Analysis]
35 Maderna P, Godson C. Lipoxins: resolutionary road. Br J Pharmacol 2009;158:947-59. [PMID: 19785661 DOI: 10.1111/j.1476-5381.2009.00386.x] [Cited by in Crossref: 150] [Cited by in F6Publishing: 136] [Article Influence: 11.5] [Reference Citation Analysis]
36 Imai Y. Role of omega-3 PUFA-derived mediators, the protectins, in influenza virus infection. Biochim Biophys Acta 2015;1851:496-502. [PMID: 25617737 DOI: 10.1016/j.bbalip.2015.01.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
37 Wu SH, Yin PL, Zhang YM, Tao HX. Reversed changes of lipoxin A4 and leukotrienes in children with asthma in different severity degree. Pediatr Pulmonol 2010;45:333-40. [PMID: 20232472 DOI: 10.1002/ppul.21186] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
38 Ricklefs I, Barkas I, Duvall MG, Cernadas M, Grossman NL, Israel E, Bleecker ER, Castro M, Erzurum SC, Fahy JV, Gaston BM, Denlinger LC, Mauger DT, Wenzel SE, Comhair SA, Coverstone AM, Fajt ML, Hastie AT, Johansson MW, Peters MC, Phillips BR, Levy BD; National Heart Lung and Blood Institute’s Severe Asthma Research Program-3 Investigators. ALX receptor ligands define a biochemical endotype for severe asthma. JCI Insight 2017;2:93534. [PMID: 28724795 DOI: 10.1172/jci.insight.93534] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
39 Starosta V, Pazdrak K, Boldogh I, Svider T, Kurosky A. Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes. J Immunol 2008;181:8688-99. [PMID: 19050289 DOI: 10.4049/jimmunol.181.12.8688] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
40 Dakin SG, Martinez FO, Yapp C, Wells G, Oppermann U, Dean BJ, Smith RD, Wheway K, Watkins B, Roche L, Carr AJ. Inflammation activation and resolution in human tendon disease. Sci Transl Med 2015;7:311ra173. [PMID: 26511510 DOI: 10.1126/scitranslmed.aac4269] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 19.3] [Reference Citation Analysis]
41 Dakin SG. A review of the healing processes in equine superficial digital flexor tendinopathy. Equine Vet Educ 2017;29:516-20. [DOI: 10.1111/eve.12572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Krishnamoorthy N, Abdulnour RE, Walker KH, Engstrom BD, Levy BD. Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases. Physiol Rev 2018;98:1335-70. [PMID: 29717929 DOI: 10.1152/physrev.00026.2017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
43 Planagumà A, Domenech T, Jover I, Ramos I, Sentellas S, Malhotra R, Miralpeix M. Lack of activity of 15-epi-lipoxin A₄ on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function. Clin Exp Immunol 2013;173:298-309. [PMID: 23607720 DOI: 10.1111/cei.12110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
44 Duvall MG, Bruggemann TR, Levy BD. Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation. Mol Aspects Med 2017;58:44-56. [PMID: 28455109 DOI: 10.1016/j.mam.2017.04.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
45 Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br J Dermatol 2013;168:172-8. [PMID: 22834636 DOI: 10.1111/j.1365-2133.2012.11177.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 85] [Article Influence: 9.4] [Reference Citation Analysis]
46 Chen J, Li W, Yao H, Xu J. Insights into drug discovery from natural products through structural modification. Fitoterapia 2015;103:231-41. [PMID: 25917513 DOI: 10.1016/j.fitote.2015.04.012] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 9.4] [Reference Citation Analysis]
47 Li G, Wu P, Xu Y, Yu Y, Sun L, Zhu L, Ye D. The effect of Lipoxin A4 on the interaction between macrophage and osteoblast: possible role in the treatment of aseptic loosening. BMC Musculoskelet Disord 2009;10:57. [PMID: 19490628 DOI: 10.1186/1471-2474-10-57] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
48 Hasan RA, OʼBrien E, Mancuso P. Lipoxin A(4) and 8-isoprostane in the exhaled breath condensate of children hospitalized for status asthmaticus. Pediatr Crit Care Med 2012;13:141-5. [PMID: 21666533 DOI: 10.1097/PCC.0b013e3182231644] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
49 Pascoal LB, Palma BB, Chaim FHM, de Castro MM, Damázio TA, Franceschini APMF, Milanski M, Velloso LA, Leal RF. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease. World J Exp Med 2022; 12(1): 1-15 [DOI: 10.5493/wjem.v12.i1.1] [Reference Citation Analysis]
50 Janakiram NB, Mohammed A, Rao CV. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev. 2011;30:507-523. [PMID: 22015691 DOI: 10.1007/s10555-011-9311-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
51 Peebles RS Jr. A new horizon in asthma: inhibiting ILC function. Sci Transl Med 2013;5:174fs7. [PMID: 23447016 DOI: 10.1126/scitranslmed.3005881] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
52 Livshits G, Kalinkovich A. Receptors for pro-resolving mediators as a therapeutic tool for smooth muscle remodeling-associated disorders. Pharmacol Res 2021;164:105340. [PMID: 33276103 DOI: 10.1016/j.phrs.2020.105340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Barnig C, Frossard N, Levy BD. Towards targeting resolution pathways of airway inflammation in asthma. Pharmacol Ther 2018;186:98-113. [PMID: 29352860 DOI: 10.1016/j.pharmthera.2018.01.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
54 Liu Y, Wei L, He C, Chen R, Meng L. Lipoxin A4 inhibits ovalbumin-induced airway inflammation and airway remodeling in a mouse model of asthma. Chem Biol Interact 2021;349:109660. [PMID: 34537180 DOI: 10.1016/j.cbi.2021.109660] [Reference Citation Analysis]
55 Cadavid AP. Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications. Front Immunol 2017;8:261. [PMID: 28360907 DOI: 10.3389/fimmu.2017.00261] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
56 Sehanobish E, Asad M, Barbi M, Porcelli SA, Jerschow E. Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease. Front Immunol 2021;12:695815. [PMID: 34305932 DOI: 10.3389/fimmu.2021.695815] [Reference Citation Analysis]
57 Ueda T, Fukunaga K, Seki H, Miyata J, Arita M, Miyasho T, Obata T, Asano K, Betsuyaku T, Takeda J. Combination Therapy of 15-Epi-Lipoxin A4 With Antibiotics Protects Mice From Escherichia coli–Induced Sepsis*: . Critical Care Medicine 2014;42:e288-95. [DOI: 10.1097/ccm.0000000000000162] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
58 Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol. 2009;158:960-971. [PMID: 19594757 DOI: 10.1111/j.1476-5381.2009.00290.x] [Cited by in Crossref: 176] [Cited by in F6Publishing: 167] [Article Influence: 13.5] [Reference Citation Analysis]
59 Thatcher TH, Woeller CF, McCarthy CE, Sime PJ. Quenching the fires: Pro-resolving mediators, air pollution, and smoking. Pharmacol Ther 2019;197:212-24. [PMID: 30759375 DOI: 10.1016/j.pharmthera.2019.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
60 Van Hove CL, Maes T, Joos GF, Tournoy KG. Chronic inflammation in asthma: a contest of persistence vs resolution. Allergy 2008;63:1095-109. [PMID: 18616676 DOI: 10.1111/j.1398-9995.2008.01772.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
61 Miyata J, Yokokura Y, Moro K, Arai H, Fukunaga K, Arita M. 12/15-Lipoxygenase Regulates IL-33-Induced Eosinophilic Airway Inflammation in Mice. Front Immunol 2021;12:687192. [PMID: 34093589 DOI: 10.3389/fimmu.2021.687192] [Reference Citation Analysis]
62 Yamaguchi H, Higashi N, Mita H, Ono E, Komase Y, Nakagawa T, Miyazawa T, Akiyama K, Taniguchi M. Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. Clin Exp Allergy 2011;41:1711-8. [PMID: 22093074 DOI: 10.1111/j.1365-2222.2011.03839.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
63 Planagumà A, Kazani S, Marigowda G, Haworth O, Mariani TJ, Israel E, Bleecker ER, Curran-Everett D, Erzurum SC, Calhoun WJ, Castro M, Chung KF, Gaston B, Jarjour NN, Busse WW, Wenzel SE, Levy BD. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008;178:574-82. [PMID: 18583575 DOI: 10.1164/rccm.200801-061OC] [Cited by in Crossref: 166] [Cited by in F6Publishing: 77] [Article Influence: 11.9] [Reference Citation Analysis]
64 Xia J, Zhou XL, Zhao Y, Zhu YQ, Jiang S, Ni SZ. Roles of lipoxin A4 in preventing paracetamol-induced acute hepatic injury in a rabbit model. Inflammation 2013;36:1431-9. [PMID: 23851615 DOI: 10.1007/s10753-013-9683-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
65 Kong X, Wu SH, Zhang L, Chen XQ. Roles of lipoxin A4 receptor activation and anti-interleukin-1β antibody on the toll-like receptor 2/mycloid differentiation factor 88/nuclear factor-κB pathway in airway inflammation induced by ovalbumin. Mol Med Rep 2015;12:895-904. [PMID: 25760938 DOI: 10.3892/mmr.2015.3443] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
66 Uddin M, Levy BD. Resolvins: natural agonists for resolution of pulmonary inflammation. Prog Lipid Res 2011;50:75-88. [PMID: 20887750 DOI: 10.1016/j.plipres.2010.09.002] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
67 Romano M, Cianci E, Simiele F, Recchiuti A. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. European Journal of Pharmacology 2015;760:49-63. [DOI: 10.1016/j.ejphar.2015.03.083] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 12.6] [Reference Citation Analysis]
68 Balgoma D, Checa A, Sar DG, Snowden S, Wheelock CE. Quantitative metabolic profiling of lipid mediators. Mol Nutr Food Res 2013;57:1359-77. [PMID: 23828856 DOI: 10.1002/mnfr.201200840] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
69 Debeuf N, Lambrecht BN. Eicosanoid Control Over Antigen Presenting Cells in Asthma. Front Immunol 2018;9:2006. [PMID: 30233591 DOI: 10.3389/fimmu.2018.02006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
70 Lotfi R, Rezaiemanesh A, Mortazavi SH, Karaji AG, Salari F. Immunoresolvents in asthma and allergic diseases: Review and update. J Cell Physiol 2019;234:8579-96. [PMID: 30488527 DOI: 10.1002/jcp.27836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
71 Bhavsar PK, Levy BD, Hew MJ, Pfeffer MA, Kazani S, Israel E, Chung KF. Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma. Respir Res 2010;11:71. [PMID: 20529300 DOI: 10.1186/1465-9921-11-71] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
72 Wang CS, Baker OJ. The G-Protein-Coupled Receptor ALX/Fpr2 Regulates Adaptive Immune Responses in Mouse Submandibular Glands. Am J Pathol 2018;188:1555-62. [PMID: 29684359 DOI: 10.1016/j.ajpath.2018.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
73 Miyata J, Arita M. Role of omega-3 fatty acids and their metabolites in asthma and allergic diseases. Allergology International 2015;64:27-34. [DOI: 10.1016/j.alit.2014.08.003] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 15.3] [Reference Citation Analysis]
74 Krönke G, Katzenbeisser J, Uderhardt S, Zaiss MM, Scholtysek C, Schabbauer G, Zarbock A, Koenders MI, Axmann R, Zwerina J, Baenckler HW, van den Berg W, Voll RE, Kühn H, Joosten LA, Schett G. 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol 2009;183:3383-9. [PMID: 19675173 DOI: 10.4049/jimmunol.0900327] [Cited by in Crossref: 104] [Cited by in F6Publishing: 102] [Article Influence: 8.0] [Reference Citation Analysis]
75 Dias IHK, Griffiths HR. Current and Future Directions for Targeting Lipoxin A4 in Alzheimer's Disease. J Alzheimers Dis 2021;81:87-90. [PMID: 33720904 DOI: 10.3233/JAD-210121] [Reference Citation Analysis]
76 Sousa LP, Pinho V, Teixeira MM. Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19? Br J Pharmacol 2020;177:3898-904. [PMID: 32557557 DOI: 10.1111/bph.15164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
77 Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-87. [PMID: 18805336 DOI: 10.1016/S0140-6736(08)61449-X] [Cited by in Crossref: 163] [Cited by in F6Publishing: 50] [Article Influence: 11.6] [Reference Citation Analysis]
78 Andrews D, Godson C. Lipoxins and synthetic lipoxin mimetics: Therapeutic potential in renal diseases. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158940. [PMID: 33839296 DOI: 10.1016/j.bbalip.2021.158940] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Smith HK, Gil CD, Oliani SM, Gavins FN. Targeting formyl peptide receptor 2 reduces leukocyte-endothelial interactions in a murine model of stroke. FASEB J 2015;29:2161-71. [PMID: 25690650 DOI: 10.1096/fj.14-263160] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
80 Chen XQ, Wu SH, Zhou Y, Tang YR. Lipoxin A4-induced heme oxygenase-1 protects cardiomyocytes against hypoxia/reoxygenation injury via p38 MAPK activation and Nrf2/ARE complex. PLoS One 2013;8:e67120. [PMID: 23826208 DOI: 10.1371/journal.pone.0067120] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]